Wobenzym tablets, coated solution-kit, 200 pcs.

Active substances: 
Pancreatin 345 prot. Heb. Farm.- ed.,

papain 90 FIP-Unit,

rutoside 3 H2O 50.00 mg,

bromelain 225 FIP-Unit.,

trypsin 360 FIP-Unit ..

lipase 34 FIP-Unit ..

amylase 50 FIP-Unit,

chymotrypsin 300 FIP-Unit 

Excipients:
Lactose,

corn starch,

magnesium stearate,

stearic acid

purified water,

silicon dioxide colloidal, talc. 
Sucrose

talc,

methacrylic acid-methyl methacrylate copolymer,

shellac,

titanium dioxide

White clay,

yellow-orange dye S (E110),

crimson dye 4R (E124),

povidone

macrogol 6000,

triethyl citrate

vanillin,

bleached wax

carnauba wax.

The combined drug. It is a combination of highly active enzymes of plant and animal origin. It has immunomodulatory, anti-inflammatory, fibrinolytic, decongestant, antiplatelet and secondary analgesic effects.

Wobenzym has a positive effect on the course of the inflammatory process, limits the pathological manifestations of autoimmune and immunocomplex processes, and positively affects the immunological reactivity of the body. Stimulates and regulates the functional activity of monocyte macrophages, natural killers (Natural killers), stimulates antitumor immunity, cytotoxic T-lymphocytes, phagocytic activity of cells.

Under the influence of Wobenzym, the number of circulating immune complexes decreases and membrane deposits of immune complexes are eliminated from the tissues.

Wobenzym reduces interstitial infiltration by plasma cells. It increases the elimination of protein detritus and fibrin deposits in the area of ​​inflammation, accelerates the lysis of toxic metabolic products and dying tissues; improves resorption of hematomas and edema; normalizes the permeability of the walls of blood vessels.

Wobenzym reduces the concentration of thromboxane and platelet aggregation. Regulates the adhesion of blood cells, increases the ability of red blood cells to change their shape, regulating their plasticity; normalizes the number of normal discocytes (platelets) and reduces the total number of activated forms of platelets, normalizes blood viscosity, reduces the total number of microaggregants, thereby improving microcirculation and rheological properties of blood, as well as supplying tissues with oxygen and nutrients.

Wobenzym normalizes lipid metabolism, reduces the synthesis of endogenous cholesterol, increases HDL, reduces atherogenic lipids, and improves the absorption of polyunsaturated fatty acids.

Wobenzym increases the effectiveness of antibiotic therapy, increasing the concentration of antibiotics in the blood plasma and the focus of inflammation, and also reduces the side effects of antibiotics (dysbiosis).

Wobenzym reduces the severity of side effects associated with the use of hormonal drugs (including hypercoagulation).

Wobenzym regulates the mechanisms of non-specific protection (production of interferons), thereby exhibiting antiviral and antimicrobial effects.

The secondary analgesic effect of Wobenzym is manifested through exposure to the causative factors of the acute inflammatory process.

For adults

As part of complex therapy:

• Thrombophlebitis (including acute thrombophlebitis of superficial veins), postphlebitis syndrome, obliterating endarteritis and atherosclerosis of lower limb arteries, lymphatic edema, prevention of recurrent phlebitis;
• Cystitis, cystopyelitis, prostatitis;
• Sexually transmitted infections
• Chronic infections of genitalia, gestosis, mastopathy, adnexitis, to reduce the frequency and severity of side effects of hormone replacement therapy in gynecology;
• Angina pectoris, subacute stage of myocardial infarction (to improve the rheological properties of blood);
• Sinusitis, bronchitis, pneumonia;
• Pancreatitis, hepatitis;
• Pyelonephritis, glomerulonephritis;
• Diabetic angiopathy, diabetic retinopathy;
• Autoimmune thyroiditis;
• Rheumatoid arthritis, reactive arthritis, ankylosing spondylitis;
• Atopic dermatitis, acne;
• Multiple sclerosis;
• Uveitis, iridocyclitis, hemophthalmus in ophthalmic surgery;
• Treatment of postoperative complications (inflammatory processes, thrombosis, edema), adhesive disease, post-traumatic and lymphatic edema, plastic and reconstructive operations;
• Injuries, fractures, distortions, dislocations, bruises, chronic post-traumatic processes, soft tissue inflammation, burns, injuries in sports medicine;
• rheumatoid arthritis;
• bronchitis, pneumonia;
• pancreatitis
• atopic dermatitis;
• prevention of atherosclerosis.

Prevention

• Microcirculatory disorders, post-stress disorders, as well as disruption of adaptation mechanisms;
• Side effects of hormone replacement therapy, hormonal contraception;
• Viral infections and their complications;
• Infectious complications and improving the quality of life during chemotherapy or radiation therapy;
• During surgical interventions to prevent infectious complications and adhesive disease.

 For children

As part of complex therapy:

• Atopic dermatitis;
• Infectious and inflammatory diseases of the respiratory tract (inflammation of the upper and lower respiratory tract, pneumonia);
• Juvenile rheumatoid arthritis.

Prevention and treatment of postoperative complications (infectious complications, poor wound healing, adhesion formation, local edema).

With caution and under the supervision of a physician, Wobenzym should be prescribed during pregnancy and lactation.

Diseases associated with an increased likelihood of bleeding (including hemophilia, thrombocytopenia);

hemodialysis; children's age up to 5 years; individual intolerance to the drug.

Wobenzym is generally well tolerated by patients.

In most cases, side effects, withdrawal syndrome, addiction were not observed even with prolonged use in high doses.

In some cases: slight changes in the consistency and smell of feces, urticaria (occur with a decrease in dose or drug withdrawal).

The patient should be warned that with the appearance of other adverse reactions, it is recommended to cancel the drug and consult a doctor.

With the simultaneous administration of Wobenzym with other drugs, cases of incompatibility are unknown.

Set individually depending on the severity of the disease.

Adults, depending on the activity and severity of the disease, are prescribed in a dose of 3 to 10 tablets. 3 times / day In the first 3 days of taking the drug, the recommended dose is 3 tablets. 3 times / day

With an average activity of the disease, the drug is prescribed in a dose of 5-7 tablets. 3 times / day for 2 weeks. In the future, the dose should be reduced to 3-5 tab. 3 times / day The course is 2 weeks.

With a high activity of the disease, the drug is prescribed in a dose of 7-10 tab. 3 times / day for 2-3 weeks. In the future, the dose should be reduced to 5 tab. 3 times / day The course is 2-3 months.

In chronic long-term diseases, Wobenzym can be used according to indications in courses of 3 to 6 months or more.

In order to increase the effectiveness of antibiotics and the prevention of dysbiosis, Wobenzym should be used throughout the course of antibiotic therapy in a dose of 5 tablets. 3 times / day After the termination of the course of antibiotic therapy to restore the intestinal microflora, Wobenzym should be prescribed 3 tablets. 3 times / day for 2 weeks.

During radiation and chemotherapy, Wobenzym should be used in a dose of 5 tablets. 3 times / day until the completion of the course of radiation and chemotherapy in order to prevent infectious complications, improve tolerance to basic therapy and improve the quality of life.

For preventive purposes, Wobenzym is prescribed 3 tablets. 3 times / day for 1.5 months with a repetition of the course 2-3 times a year.

Children aged 5-12 years are prescribed in a daily dose at the rate of 1 tab. per 6 kg of body weight. For children over 12 years of age, the drug is prescribed according to the scheme intended for adults. The duration of treatment is determined individually.

The drug should be taken at least 30 minutes before meals, without chewing, washed down with water (200 ml).

No cases of overdose of Wobenzym have been reported.

In the case of infectious processes, WOBENZYM does not replace antibiotics, but increases their effectiveness by increasing the concentration in the blood plasma and the focus of inflammation.

It should be borne in mind that at the very beginning of taking the drug, the symptoms of the disease may worsen, in such cases treatment should not be interrupted, and a temporary reduction in the dose of the drug is recommended.

The drug is not doping and does not adversely affect car driving and the performance of work that requires a high speed of mental and physical reactions.

Enteric-coated tablets of red-orange color, round, biconvex, with a smooth surface, with a characteristic odor; fluctuations in the intensity of the color of the outer shell from red-orange to red are allowed.